Atai Life Sciences Co-Ceo Says Initial Results From Ele-101 Show Promise In Treating Depression

atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression

Proactive Investors

Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder

atai Life Sciences outlines key milestones in psychedelic therapy for depression in 2023 and 2024

Proactive Investors

atai Life Sciences advances VLS-01 for treatment-resistant depression

Proactive Investors

Atai Life Sciences founder on using psychedelics to treat mental illness

CNBC Television

Atai Life Sciences 'bringing innovation to mental healthcare and treatment addiction'

Proactive Investors

Atai Life Sciences, Compass Pathways, MindMed & Cybin's Q3 Financial Results Analysis - What's Next?

Psychedelics for Depression: The Promise, Risks, & Costs - Srinivas Rao (Mapping the Mind 2019)

Mapping the Mind

Florian Brand Talks of Innovation in Mental Healthcare to Tackle Depression, Anxiety and Addiction

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients |#shorts

ATAI Life Science founder, Christian Angermayer, talks about his psilocybin mushroom use

Atai Life Sciences: Clear Leader In Psychedelics Has Huge Upside

The Futurist Investor

End-of-Life Expert Susan Tolle on Rolling Out Physicians Orders for Life-Sustaining Treatment

California Health Care Foundation

Psychedelics might change mental healthcare. Will investors follow?

CNBC International

Psilocybin Found To Rapidly Improve Depressive Symptoms In Patients

APA 2018 Opening Session Recap

WebsEdgeMedicine

atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks

"Expectation vs. Reality" - Elian Pusceddu, Gaia Membranes

Keynote speech on "How data impacts lives towards a zero patients vision by 2030" by Dr. Elia Stupka

Earth Day 2009: Reflections on our planet and its life

MIT Energy Initiative